GEN Exclusives

More »

GEN News Highlights

More »
Dec 9, 2010

Phase III Trial Demonstrates Benefits of Teva’s Laquinimod in MS Patients

  • Phase III trial data has demonstrated that treatment using the oral immunomodulatory candidate laquinimod leads to significant reductions in annualized relapse rates in patients with relapsing-remitting multiple sclerosis (MS), Teva Pharmaceuticals reports. The drug also led to significant reductions in disability progression, as measured by the Expanded Disability Severity Scale.

    The pivotal placebo-controlled Allegro trial involved 1,106 MS patients in 24 countries, and evaluated the safety and efficacy of once-daily laquinimod in comparison with placebo. The primary efficacy outcome was the number of confirmed relapses. Secondary measures included confirmed disability progression and changes in MRI-evaluated active lesions.

    Allegro was the first of two Phase III studies with laquinimod in MS patients. Results from the completed Bravo trial are expected during the latter part of 2011. This placebo-controlled trial in 1,332 patients compared the safety, efficacy, and tolerability of laquinimod therapy with treatment using interferon beta-1a. Laquinimod is separately undergoing Phase II development for the treatment of Crohn’s disease and lupus nephritis.

    Teva negotiated exclusive worldwide rights to develop, register, manufacture, and commercialize laquinimod from Active Biotech in 2004. Under terms of the deal Active received an up-front fee of $5 million, and could be eligible to development, regulatory, and sales milestones of $92 million, plus double-digit sales royalties. Teva is responsible for carrying out and funding all clinical development of the drug. Laquinimod received fast-track designation from the FDA in 2009.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »